Abstract: It has been discovered that HSP90 inhibitors can inhibit both the pro-inflammatory and pro-coagulatory potential of monocytes, in particular activated monocytes. One embodiment provides a method of inhibiting the pro-inflammatory phenotype of monocytes, preferably in human subjects, most preferably in human subjects having Sickle Cell Disease (SCD). A preferred HSP90 inhibitor is 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide (NVP-AUY922).

Abstract: Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.

Abstract: Methods are disclosed to enhance the training potential of a domestic animal during training, thereby shortening the training period and/or increasing the effectiveness of the training. The method involves first administering to the domestic animal a pharmaceutical composition comprising a cognitive enhancing agent in an amount effective to improve cognitive function. The enhanced cognition allows the domestic animal to learn to perform a task and/or to change its existing behavior more effectively and on an accelerated basis. Therefore, while the animal's cognitive function is enhanced, the method then involves conditioning the domestic animal to perform a task or change an existing behavior.

Abstract: The invention discloses a method of treatment for various severe disorders which is not treated well by current FDA approved drugs. The therapeutic agents by the method are compounds or biological agents which pass safety tests in the clinical trials, but not pass the efficacy test, as safety of those compounds or biological agents are comparable with any ones in the market which pass both safety and efficacy tests in the clinical trials, combined application of those compounds or biological agents can significantly improve varied severe medical conditions.

Abstract: A method of treating or preventing a condition caused by a biofilm in a subject is carried out by: providing a subject having, or susceptible to, a condition mediated by a biofilm produced by a microorganism, where the biofilm comprises a matrix and the microorganism on a surface and administering to the subject an active agent under conditions effective for the condition caused by a biofilm in the subject to be treated or prevented, where the active agent is a compound of general Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: The invention generally relates to methods for treating and/or reducing the severity of a wound in a subject. Provided are wound therapies combining low level light therapy (LLLT) and a nitric oxide (NO) donor to treat and/or reduce the severity of the wound. The LLLT and NO donor may be administered concurrently or sequentially. Also provided are wound treatment systems and kits including a light source and a NO donor, which are administered to a wounded subject. Further provided are pharmaceutical compositions that comprise a NO donor and are formulated to be administered in conjunction with LLLT.

Abstract: The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).

Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.

Abstract: The present invention provides dry powder formulations for inhalation having improved moisture resistance such that the powders maintain a high fine particle dosage or fine particle fraction following storage under relatively extreme temperature and humidity conditions.

Abstract: Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval.

Abstract: The present invention relates to testosterone topical formulations, especially high testosterone concentration formulations, such as between about 6% to about 15% w/w or higher, for the controlled release of testosterone into the systemic circulation of males and females for providing constant effective testosterone blood levels, without inducing undesired testosterone spike in blood levels or testosterone transference, following topical administration. The testosterone topical formulations of the present invention are safe, convenient to use, well tolerated, stable and easily and reproducibly manufactured on scale up. Moreover, because supra-normal and sub-normal testosterone blood levels are believed to be essentially kept to a minimum or avoided and the testosterone serum levels are believed to remain essentially constant during dose life, i.e.

Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.

Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

Abstract: This invention relates to solid oral dosage forms of the HIV inhibitor darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof.

Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.

Abstract: A method of treating a disease comprising administering to a subject a therapeutically effective amount of a compound that includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.

Abstract: The present application discloses a synthetic mixture of oligosaccharides for treating a microbiota of a mammal, preferably a human, to reduce or eliminate the activity and/or the proportion of a microbe in the microbiota that is associated with the development or maintenance of a disease or an unhealthy condition of the mammal, e.g.

Abstract: A method for treating NAFLD and/or NASH and suitable compositions for carrying out the method are claimed.

Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.

Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.

Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.

Abstract: Described are compounds capable of modulating (a) the biological activity of ADP-dependent glucokinase (ADPGK) and/or glycerol-3-phosphate dehydrogenase (GPD2) or (b) the expression of the gene encoding ADPGK or GPD2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system, e.g., an autoimmune disease.

Abstract: The present invention relates to the use of heparin derivatives for the prevention and/or treatment of cancer and/or cancer metastasis. The heparin derivatives are substantially 2-O and/or 6-O desulphated heparins which function as inhibitors of galectin-3 activity.

Abstract: The present invention relates to new synergistic associations of hyaluronic acid sodium salt (HANa), verbascoside (VB) and glycero-phospho-inositol (GPI), and the use of said associations in therapy, in particular in the topical treatment of inflammatory and painful conditions of the mucosa and/or skin, such as dermatitis, acne, psoriasis, ulcers, decubitus ulcers, phlebitis, hemorrhoids, and in particular vulvodynia and urethritis.

Abstract: A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed.

Abstract: The present invention provides methods for treating or preventing diseases and disorders caused by iron-dependent pathogenic microorganisms, such as bacteria, fungi, and parasites, by applying a gallium compound to an affected area. In particular, the present invention provides methods for treating or preventing dental caries, vaginal infections, skin infections, and so forth. Gallium compounds can be formulated as toothpaste, mouthwash, cream, ointment, gel, solution, eye drops, suppository, and the like. Furthermore, the invention provides methods for controlling microbial growth on environmental surfaces, including those of toothbrush, denture, dental retainer, contact lens, catheter, food stuff, and so forth. In addition, the present invention provides animal feeds which contain gallium compounds that promote the animal growth and prevent the animals from infections as well as protect consumers from post processing infections.

Abstract: A composition and system for the treatment of irritations of the skin includes therapeutically effective amounts of tincture benzoin and zinc oxide; a therapeutically effective amount of Castor oil, used as an epidermal permeation enhancer; and a therapeutically effective amount of petroleum jelly used as a moisturizing agent.

Abstract: Methods of treating a gastrointestinal spasms associated with chemotherapy or radiation therapy are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.

Abstract: The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.

Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of KHYG-1 cell medium and methods of using the compositions for killing cancer cells and infected cells in a human patient or animal.

Abstract: The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects.

Abstract: A method and a pharmaceutical composition for treating an atherosclerotic lesion are provided, including administering a subject in need thereof a therapeutically effective amount of a composition comprising hypoxia-cultured MSCs obtained by culturing auto- or allo-MSCs under low oxygen conditions.

Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury.

Abstract: It is a problem of the present invention to provide a convenient and safe periodontal tissue regeneration material and provide a method of regenerating a periodontal tissue. The present invention provides a periodontal tissue regeneration material comprising dedifferentiated fat cells (DFAT) as the convenient and safe periodontal tissue regeneration material. The present invention provides a method of regenerating a periodontal tissue with the periodontal tissue regeneration material.

Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.

Abstract: A product for use in the treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimers disease and inflammatory bowel disease comprising at least one isolated bacterial strain from the species Prevotellaceae, wherein the strain is selected from the group consisting of Prevotella copri, Prevotella stercorea, Prevotella histicola, Prevotella ruminicola, Prevotella Bryantii 25A and Prevotella distasonis. The product may be a food product.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.

Abstract: An anti-oxidative Lactobacillus rhamnosus CCFM1107 can relieve chronic alcoholic liver injury, and L. rhamnosus CCFM1107 can be used in preparing dairy products as starter culture. The dairy products of this invention include milk, milk powder, milk capsules or fermented milk containing L. rhamnosus CCFM1107. It has strong abilities of anti-oxidation, scavenging diphenyl picrylhydrazyl (DPPH) radical and hydroxyl radical, inhibiting lipid peroxidation, tolerating cholate, chlorine sodium and pH, and can improve liver function and antioxidative index, lower serum endotoxin level and regulate intestinal flora distribution, thus effectively relieving alcoholic liver injury of mice.

Abstract: The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.

Abstract: The present application relates to compositions comprising selenium (e.g., selenium enriched yeast) and methods of using the same to treat and inhibit obesity, diabetes and related conditions. In particular, the present application provides compositions comprising selenium enriched yeast (e.g., selenium enriched yeast comprising 2% or less inorganic selenium), and methods of using the same to enhance mitochondrial activity and function (e.g., in skeletal muscle and liver) in a subject (e.g., as a therapeutic and/or prophylactic treatment for diabetes, obesity and related conditions).

Abstract: A pharmaceutical composition for the topical or parenteral administration useful for the prophylaxis and treatment of diseases with infectious aetiology, both viral and bacterial diseases, in particular diseases affecting the oral cavity, such as gingivitis, periodontitis and perimplantitis.

Abstract: The present invention relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present invention relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.

Abstract: The present invention relates to a new extract of Cassia acutifolia and/or Cassia angustifolia in which only traces of total sennosides and resins are present, a process for the preparation of said extract, compositions comprising it, and the use of the extract and of the compositions for the protection of the skin or mucous membranes.

Abstract: A topical composition is provided that includes at least three plant extracts selected from the group consisting of: lavender, calendula, rosemary, peppermint, myrrh, frankincense, helichrysum and aloe. The plant extracts in are dissolved or suspended in a carrier. The topical composition in some embodiments has each of said at least three plant extracts present in an amount of from 0.1 to 60 total weight percent of an inventive composition, with the total amount of plant extracts being between 2 and 90 total weight percent. A method of treating irradiated skin includes the application of such a composition to skin after medical irradiation, then allowing sufficient time for the skin to heal. A method of inhibiting radiation dermatitis includes the application of such a composition to skin prior to medical irradiation, then irradiating the skin ionizing radiation.

Abstract: A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of the above with Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi.

Abstract: A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of the above with Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi.

Abstract: The present invention relates to an oily extract of plants of Rubus species and uses thereof in medical and cosmetic fields. In more detail, the invention relates to the use of an oily extract of plants of Rubus species and the topical treatment of cutaneous and mucosal pathologies and skin lesions. The invention further concerns a method for obtaining such extract through extraction in oil at room temperature.

Abstract: The present invention features a composition and method for reducing food intake. The composition of the invention is composed of yerbe maté extract, guarana extract, and damiana extract in combination with a dietary fiber.